The Single Biggest Cannabis Catalyst in Years Is Rapidly Approaching: 2 Marijuana Stocks to Buy Now

Cannabis reclassification to Schedule III could let medical marijuana firms take standard tax deductions under 280E, with possible additional benefits if adult-use marijuana is also rescheduled. The article highlights Green Thumb Industries and Tilray as better-positioned names, citing Green Thumb's $300.2 million Q1 revenue, $0.07 EPS, and net cash position of $54.6 million, while Tilray reported $206.7 million in quarterly revenue, 73% international sales growth, and reduced debt to $549 million. Near-term upside is tempered by legal challenges from three states and uncertainty around SAFER Banking and past tax liabilities.

Analysis

The market is pricing a regulatory delta, but the real earnings lever is tax normalization. The first-order winner is whichever operator can convert 280E relief into free cash flow fastest; that favors balance-sheet quality and existing positive EBITDA over pure revenue growth. In that framing, TLRY is less a direct cannabis beta than a call option on cross-border distribution optionality and beverage infrastructure, while the more immediate re-rating candidate is the operator with the cleanest path to de-lever without equity dilution.

The second-order effect is competitive, not just sector-wide. If federal treatment improves, capital will likely rotate toward branded operators with pricing power and away from commodity-like retail footprints, because tax savings will be disproportionately captured by companies that can defend gross margin. That also means the long-tail beneficiaries may be ancillary channels — beverage distribution, infused products, and healthcare-adjacent hemp supply chains — rather than the most obvious MSOs that rallied hardest on the headline.

The main risk is timing dispersion: the stock response can decouple from the policy outcome for months if the litigation or hearings push the effective date out, and the market may already be discounting a best-case sequence. Any reversal in the regulatory path would hit the most levered names first, while the cleaner balance-sheet names should hold up better. The consensus is likely underestimating how much of this move is a tax story versus a legalization story; if 280E relief is delayed or narrowed, upside on the crowded cannabis beta names becomes much less durable.

From a trade perspective, the better expression is relative value rather than outright long cannabis. TLRY offers asymmetric upside if U.S. distribution unlocks, but it should be sized as a medium-dated catalyst trade, not a core holding. Green Thumb is the lower-volatility way to own the thesis, but after the move in the space, the better risk/reward may be to own quality and fade the most crowded MSO leaders if the policy calendar slips.

Key Decisions for Investors

• Long TLRY vs. short a basket of high-beta MSOs for 3-6 months: express optionality on U.S. expansion while hedging sector-wide regulatory disappointment; target asymmetric upside if hearings advance, cut if policy slips beyond the next quarter.
• Overweight GTBIF on pullbacks as the cleaner fundamental winner over 6-12 months: positive cash balance, existing profitability, and brand mix make it the best vehicle for 280E normalization with lower dilution risk.
• Avoid chasing the strongest recent rally names in the sector until litigation risk resolves: use the next 2-6 weeks to wait for a better entry rather than paying for already-extended expectations.
• If options liquidity allows, buy medium-dated calls on TLRY and finance with short-dated call spreads against sector peers: keeps upside to a favorable U.S. regulatory surprise while limiting theta if hearings stall.
• Set a stop-loss on cannabis longs tied to adverse court or hearing headlines: if federal implementation looks delayed by one quarter or more, expect a fast derating in the most speculative names.